Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock? [Yahoo! Finance]
Hims & Hers Health, Inc. Class A (HIMS)
Company Research
Source: Yahoo! Finance
The company said it was in active discussion with Novo Nordisk to bring back Wegovy to its platform. The stock looks attractively priced at current levels, given its growth outlook. 10 stocks we like better than Hims & Hers Health › Hims & Hers Health (NYSE: HIMS) demonstrated once again why it's one of the most interesting growth stocks outside of the tech sector when it reported strong Q3 results. While the stock has been volatile this year, it is trading up more than 80% in 2025, as of this writing. Let's take a closer look at the most recent earnings results for this telehealth company to see if now is a good time to buy the stock. Strong revenue growth continues Hims & Hers delivered yet another strong quarter of revenue growth in Q3, with sales climbing 49% year over year to $599 million. That was above the high end of its $570 million to $590 million guidance, and above the $582 million analyst consensus, as compiled by Factset Image source: Getty Images. Month
Show less
Read more
Impact Snapshot
Event Time:
HIMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HIMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HIMS alerts
High impacting Hims & Hers Health, Inc. Class A news events
Weekly update
A roundup of the hottest topics
HIMS
News
- Hims & Hers Health (NYSE:HIMS) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.MarketBeat
- Hims & Hers Continues Major International Expansion With Official Entry Into Canada [Yahoo! Finance]Yahoo! Finance
- A New Market, A New Catalyst: Assessing Hims & Hers' Canadian Opportunity [Seeking Alpha]Seeking Alpha
- Humana And Mark Cuban's Cost Plus Drugs Working On Partnership To Lower Prices [Forbes]Forbes
- Hims & Hers Health, Inc. (HIMS): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
HIMS
Earnings
- 11/3/25 - Miss
HIMS
Sec Filings
- 12/2/25 - Form 4
- 12/2/25 - Form 4
- 11/25/25 - Form 4
- HIMS's page on the SEC website